• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹腔镜评估腹膜癌指数及腹腔热灌注化疗(HIPEC)在腹膜转移患者中进行细胞减灭术的适应证的局限性。

Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis.

机构信息

Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.

Department of Gastroenterology, Gastrointestinal Oncology, Infectious Disease and Geriatric Medicine, University Hospital Tübingen, Otfried-Müller-Str. 8, 72076, Tübingen, Germany.

出版信息

Langenbecks Arch Surg. 2022 Jun;407(4):1667-1675. doi: 10.1007/s00423-022-02455-2. Epub 2022 Feb 2.

DOI:10.1007/s00423-022-02455-2
PMID:35112142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8809494/
Abstract

PURPOSE

We aimed to determine the value of laparoscopy to assess the intra-abdominal tumor extent and predict complete cytoreduction.

METHODS

All patients at our department in the period from 2017 to 2021 that underwent laparoscopy to assess peritoneal metastasis and subsequent open exploration with the intention to perform cytoreductive surgery (CRS) with HIPEC were retrospectively identified in a continuously maintained database.

RESULTS

Forty-three patients were analyzed. Peritoneal cancer index (PCI) determination by laparoscopy compared to open surgery was overestimated in five patients (11.6%), identical in eleven patients (25.6%), and underestimated in 27 patients (62.8%). PCI differences were independent of surgeons, tumor entities, and prior chemotherapy. Thirty-four patients (79.1%) were determined eligible for CRS with HIPEC during open exploration, whereas nine patients (20.9%) underwent a non-therapeutic laparotomy. Complete or almost complete cytoreduction was achieved in 33 patients (76.7%). In one patient, completeness of cytoreduction was not documented.

CONCLUSIONS

We demonstrate a moderate agreement according to weighted Cohen's kappa analysis of PCI values calculated during laparoscopy and subsequent open exploration for CRS with HIPEC. Uncertainty of PCI assessment should therefore be kept in mind when performing laparoscopy in patients with peritoneal metastasis.

摘要

目的

我们旨在确定腹腔镜检查评估腹腔内肿瘤范围和预测完全肿瘤减灭术的价值。

方法

我们在一个持续维护的数据库中回顾性地确定了 2017 年至 2021 年期间在我们科室接受腹腔镜检查评估腹膜转移并随后进行开放性探查以意图进行含 HIPEC 的细胞减灭术(CRS)的所有患者。

结果

分析了 43 名患者。与剖腹手术相比,腹腔镜检查确定的腹膜癌指数(PCI)在 5 名患者(11.6%)中被高估,在 11 名患者(25.6%)中被准确评估,在 27 名患者(62.8%)中被低估。PCI 差异与外科医生、肿瘤实体和先前的化疗无关。34 名患者(79.1%)在开放性探查时被确定有资格接受含 HIPEC 的 CRS,而 9 名患者(20.9%)接受了非治疗性剖腹手术。33 名患者(76.7%)实现了完全或几乎完全肿瘤减灭术。在一名患者中,肿瘤减灭术的完整性未被记录。

结论

根据用于含 HIPEC 的 CRS 的腹腔镜检查和随后的开放性探查期间计算的 PCI 值的加权 Cohen's kappa 分析,我们证明了中等程度的一致性。因此,在有腹膜转移的患者中进行腹腔镜检查时,应牢记 PCI 评估的不确定性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f127/9283349/19074f33fe3b/423_2022_2455_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f127/9283349/0c06a255d82e/423_2022_2455_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f127/9283349/19074f33fe3b/423_2022_2455_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f127/9283349/0c06a255d82e/423_2022_2455_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f127/9283349/19074f33fe3b/423_2022_2455_Fig2_HTML.jpg

相似文献

1
Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis.腹腔镜评估腹膜癌指数及腹腔热灌注化疗(HIPEC)在腹膜转移患者中进行细胞减灭术的适应证的局限性。
Langenbecks Arch Surg. 2022 Jun;407(4):1667-1675. doi: 10.1007/s00423-022-02455-2. Epub 2022 Feb 2.
2
Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.结直肠和阑尾癌腹膜转移行细胞减灭术联合腹腔热灌注化疗的短期和长期疗效:腹腔镜与开腹手术的倾向评分匹配比较。
Surg Oncol. 2022 Aug;43:101766. doi: 10.1016/j.suronc.2022.101766. Epub 2022 Apr 8.
3
[Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].1384例腹膜癌病患者接受细胞减灭术加腹腔内热灌注化疗的疗效
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25;24(3):230-239. doi: 10.3760/cma.j.cn.441530-20201110-00603.
4
Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.腹腔镜检查在腹膜转移癌患者中是安全的,不会延迟含热灌注化疗的细胞减灭术。
Am Surg. 2022 Apr;88(4):698-703. doi: 10.1177/00031348211048819. Epub 2021 Nov 3.
5
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis.腹腔镜细胞减灭术和腹腔内热化疗与改善围手术期结局相关:单中心早期经验倾向评分匹配分析。
Surg Endosc. 2022 Aug;36(8):6153-6161. doi: 10.1007/s00464-022-09034-y. Epub 2022 Jan 26.
6
Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).腹腔镜检查在考虑进行细胞减灭术和腹腔内热灌注化疗(HIPEC)的腹膜转移患者中的作用。
World J Surg Oncol. 2014 Aug 21;12:270. doi: 10.1186/1477-7819-12-270.
7
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.伴或不伴腹腔内热灌注化疗的细胞减灭术治疗伴有腹膜转移的小肠类癌。
Eur J Surg Oncol. 2022 Jul;48(7):1626-1630. doi: 10.1016/j.ejso.2022.03.019. Epub 2022 Mar 27.
8
Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.新辅助化疗联合腹腔热灌注化疗治疗结直肠腹膜转移患者的安全性和有效性:一项回顾性研究。
World J Surg Oncol. 2021 May 17;19(1):151. doi: 10.1186/s12957-021-02255-w.
9
Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.复发性腹膜癌患者的重复细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)
World J Surg Oncol. 2016 Feb 24;14(1):42. doi: 10.1186/s12957-016-0804-x.
10
Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.结直肠腹膜转移且腹膜肿瘤指数较高的患者可能从细胞减灭术和腹腔热灌注化疗中获益。
Eur J Surg Oncol. 2020 Dec;46(12):2283-2291. doi: 10.1016/j.ejso.2020.07.039. Epub 2020 Aug 5.

引用本文的文献

1
Challenges of Nontherapeutic Laparotomy in Patients with Peritoneal Surface Malignancies Selected for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.为接受细胞减灭术和腹腔内热灌注化疗而选择的腹膜表面恶性肿瘤患者进行非治疗性剖腹手术的挑战。
Cancers (Basel). 2025 Apr 25;17(9):1445. doi: 10.3390/cancers17091445.
2
Minimally Invasive Surgery: Is It a Risk Factor for Postoperative Peritoneal Metastasis in pT4 Colon Cancer?微创手术:它是pT4期结肠癌术后腹膜转移的危险因素吗?
Ann Surg Oncol. 2025 Jan;32(1):158-164. doi: 10.1245/s10434-024-16177-w. Epub 2024 Sep 16.
3
The rare occurrence of unifocal peritoneal mesothelioma: a case report, literature review, and future directions.

本文引用的文献

1
CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative.腹膜间皮瘤行细胞减灭术/腹腔热灌注化疗联合主要器官切除术对严重并发症或总生存期无影响:美国腹腔热灌注化疗协作组的一项回顾性队列研究
Ann Surg Oncol. 2020 Dec;27(13):4996-5004. doi: 10.1245/s10434-020-09232-9. Epub 2020 Oct 18.
2
Adding diagnostic laparoscopy to computed tomography for the evaluation of peritoneal metastases in patients with colorectal cancer: A retrospective cohort study.添加诊断性腹腔镜检查以评估结直肠癌患者腹膜转移的计算机断层扫描:一项回顾性队列研究。
Surg Oncol. 2020 Jun;33:135-140. doi: 10.1016/j.suronc.2020.02.010. Epub 2020 Feb 15.
3
单灶性腹膜间皮瘤的罕见病例:病例报告、文献综述及未来研究方向
J Gastrointest Oncol. 2024 Aug 31;15(4):1939-1947. doi: 10.21037/jgo-24-266. Epub 2024 Aug 20.
4
Assessment of Intraoperative Scoring Systems for Predicting Cytoreduction Outcome in Peritoneal Metastatic Disease: A Systematic Review and Meta-analysis.评估预测腹膜转移疾病细胞减灭术结局的术中评分系统:系统评价和荟萃分析。
Ann Surg Oncol. 2024 Oct;31(10):7165-7183. doi: 10.1245/s10434-024-15629-7. Epub 2024 Jun 25.
5
Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).减瘤手术(CRS)及腹腔热灌注化疗(HIPEC)的当前临床实践。
Innov Surg Sci. 2024 Mar 14;9(1):3-15. doi: 10.1515/iss-2023-0055. eCollection 2024 Mar.
6
[Surgical treatment of pseudomyxoma peritonei-Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].腹膜假黏液瘤的外科治疗——细胞减灭术及腹腔内热灌注化疗
Chirurgie (Heidelb). 2023 Oct;94(10):840-844. doi: 10.1007/s00104-023-01937-3. Epub 2023 Aug 14.
7
Letter to the Editor on Yurttas C et al. "Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis".致编辑的信:关于于尔塔斯·C等人的《腹腔镜评估腹膜癌指数及在腹膜转移中进行热灌注化疗减瘤手术的适用性的局限性》
Langenbecks Arch Surg. 2023 Jan 31;408(1):70. doi: 10.1007/s00423-023-02820-9.
8
Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS.完全细胞减灭术(CRS)后腹腔热灌注化疗(HIPEC)在铂敏感复发性卵巢癌(OC)腹膜复发中的作用:两个CRS参考中心的标准化目标
Cancers (Basel). 2023 Jan 7;15(2):405. doi: 10.3390/cancers15020405.
9
Reply to "Letter to the Editor on Yurttas C et al. Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis".对“致编辑的信:关于Yurttas C等人的研究‘腹腔镜检查评估腹膜癌指数及腹膜转移患者接受热灌注化疗减瘤手术的适用性的局限性’”的回复
Langenbecks Arch Surg. 2023 Jan 14;408(1):27. doi: 10.1007/s00423-023-02772-0.
10
Selection Criteria for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Special Emphasis on Laparoscopy as an Efficient Tool.细胞减灭术和腹腔热灌注化疗的选择标准,特别强调腹腔镜作为一种有效的工具。
In Vivo. 2022 May-Jun;36(3):1367-1374. doi: 10.21873/invivo.12840.
The Pathologic Peritoneal Cancer Index (PCI) Strongly Differs From the Surgical PCI in Peritoneal Metastases Arising From Various Primary Tumors.
原发灶不同所致腹膜转移的病理腹膜肿瘤指数(PCI)与手术 PCI 存在显著差异。
Ann Surg Oncol. 2020 Aug;27(8):2985-2996. doi: 10.1245/s10434-020-08234-x. Epub 2020 Feb 10.
4
Diagnostic Laparoscopy as a Selection Tool for Patients with Colorectal Peritoneal Metastases to Prevent a Non-therapeutic Laparotomy During Cytoreductive Surgery.诊断性腹腔镜检查作为结直肠腹膜转移患者的选择工具,以防止细胞减灭术中非治疗性剖腹手术。
Ann Surg Oncol. 2020 Apr;27(4):1084-1093. doi: 10.1245/s10434-019-07957-w. Epub 2019 Oct 22.
5
Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.结直肠癌和阑尾腹膜转移患者行 CRS 和 HIPEC 治疗前 BRAF 和 KRAS 基因突变的预后影响。
Ann Surg Oncol. 2020 Jan;27(1):293-300. doi: 10.1245/s10434-019-07452-2. Epub 2019 Sep 30.
6
RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.RAS 突变降低结直肠腹膜转移患者行最佳细胞减灭术和腹腔热灌注化疗后的总生存期:腹膜表面疾病严重程度评分的改良建议。
Ann Surg Oncol. 2019 Aug;26(8):2595-2604. doi: 10.1245/s10434-019-07378-9. Epub 2019 May 20.
7
RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer.RAS 基因突变状态为接受细胞减灭术和腹腔热灌注化疗治疗结直肠癌患者提供预后相关性。
J Surg Res. 2019 Aug;240:130-135. doi: 10.1016/j.jss.2019.02.050. Epub 2019 Mar 28.
8
Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin.RAS/RAF 原癌基因突变可损害结直肠来源腹膜转移患者细胞减灭术联合腹腔热灌注化疗后的生存
Ann Surg. 2018 Nov;268(5):845-853. doi: 10.1097/SLA.0000000000002899.
9
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.腹腔内热灌注化疗治疗卵巢癌。
N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.
10
Common pitfalls in statistical analysis: Measures of agreement.统计分析中的常见陷阱:一致性度量
Perspect Clin Res. 2017 Oct-Dec;8(4):187-191. doi: 10.4103/picr.PICR_123_17.